Cover Page

Cite item


The article highlights the main steps in the formation of compulsory licensing mechanism before the establishment of the World Trade Organization, and analyzes the main provisions of this mechanism implementation under the TRIPS Agreement and the Doha Declaration. Based on the analysis of examples from different regions of the world, the article determines the main advantages of using compulsory licensing with regard to expand of access to medicines, possible impact on quality of the medicinal products being produced and the investment attractiveness of the countries applying this mechanism are assessed. The purpose of this article is to analyze the main approaches to the implementation of compulsory licensing in order to determine the most effective strategy for using this mechanism in the Russian Federation in order to expand the availability of drug therapy for the treatment of life-threatening diseases. Based on the impact of compulsory licensing implementation, the author concludes that it does not correspond to the objectives of the Russian pharmaceutical industry development identified as a priority by Russian Government. Despite a possibility of using compulsory licensing under regulation of many countries, this mechanism is implemented rarely. A possibility of issuing a compulsory licensing is a strong argument in price negotiations with producers. According to the authors position, implementation of compulsory licensing has to be preceded by cost containment mechanism, primarily based on negotiations with producers.

About the authors

Aslan H Abashidze

Peoples' Friendship University of Russia

Author for correspondence.

Doctor of Legal Sciences, Professor, Head of the Department of International Law of the RUDN University

6, Miklukho-Maklaya st., Moscow, Russia, 117198

Vladislav S Malichenko

The Institute of legislation and comparative law under the government of the Russian federation


Candidate of Legal Sciences, Associate Professor, Senior researcher. The institute of legislation and comparative law under the government of the Russian Federation

34, B. Cheremushkinskaya st., Moscow, Russia, 117218


  1. Abashidze, A.K, Malichenko, V.S. (2013) Obespecheniye dostupa k lekarstvennym sredstvam v usloviyakh razvitiya mekhanizmov zashchity prav intellektual'noy sobstvennosti [Ensuring access to medicines in the context of intellectual property rights development]. Modern law, № 7, 2013. P. 155-157. (in Russian).
  2. Abashidze, A.K, Malichenko, V.S. (2017) Rasshireniye dostupa k lekarstvennym sredstvam v ramkakh obespecheniya prava kazhdogo cheloveka na pol'zovaniye rezul'tatami nauchnogo progressa i ikh prakticheskoye primeneniye [Expanding access to medicines in frame of the right to enjoy the benefits of scientific progress and its applications] Eurasian law journal № 5, 2017. Pp. 23-28. (in Russian).
  3. Amin, T., (2007). Voluntary licensing practices in the pharmaceutical sector: an acceptable solution to improving access to affordable medicines. Pp. 1-19. (in English).
  4. Andrieux-Meyer, I., Cohn, J., de Araújo, E. S. A., & Hamid, S. S. (2015). Disparity in market prices for hepatitis C virus direct-acting drugs. The Lancet Global Health, 3(11). Pp. e676-e677. (in English).
  5. Avafia, T., Berger, J., & Hartzenberg, T. (2006). The ability of select sub-Saharan African countries to utilize TRIPS flexibilities and competition law to ensure a sustainable supply of essential medicines: A study of producing and importing countries (Working Paper No. 12). Trade law center for Southern Africa. ICTSD, UNCTAD and tralac, Pp. 1-10. (in English).
  6. Bagchi, A. (2003). Compulsory Licensing and the Duty of Good Faith in TRIPS. Stanford Law Review, 55(5), 1529-1555. Available at: URL: [Accessed December 20th, 2018].
  7. Beall, R.F., Kuhn, R., Attaran, A. (2015). Compulsory Licensing Often Did Not Produce Lower Prices For Antiretrovirals Compared To International Procurement. HEALTH AFFAIRS 34, (3). Pp.493-501. (in English).
  8. Bermudez, J., & Hoen, E. T. (2010). The UNITAID patent pool initiative: bringing patents together for the common good. The open AIDS journal, 4, 37. (in English).
  9. Bognar, C.L.F.B., Bychkovsky, B.L., Lopes Jr, G.D.L. (2016). Compulsory licenses for cancer drugs: does circumventing patent rights improve access to oncology medications? Journal of global oncology, 2(5). Pp. 292-301. (in English).
  10. Bonadio, E., (2012). Compulsory licensing of patents: the Bayer/Natco case. Natco Case. Pp. 719-728. (in English).
  11. Chien, C. (2003). Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation? Berkeley Technology Law Journal, 18(3). Pp. 853-907. (in English).
  12. Correa, C. (2015) The use of compulsory licensing in Latin America. In: Hilty M, Liu KC. (eds.) Licensing: practical experiences and way forward. Heidelberg:Springer. Pp. 43-61. (in English).
  13. Cotter, C., (2007) The Implications of Rwanda's Paragraph 6 Agreement with Canada for Other Developing Countries. Loy. U. Chi. Int'l L. Rev., 5. Pp.177. (in English).
  14. Ecorys, B (2009) Competitiveness of the EU market and industry for pharmaceuticals. Volume II: Markets, Innovation & Regulation. European Commission, Directorate General Enterprise & Industry. (in English).
  15. Elliott, R., (2006) Pledges and pitfalls: Canada’s legislation on compulsory licensing of pharmaceuticals for export, Int. J. Intellectual Property Management, Vol. 1, Nos. ½. Pp. 94-112. (in English).
  16. Lybecker, K. M. and Fowler, E. (2009) Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure Legitimate Use of the WTO Rules. The Journal of Law, Medicine & Ethics, (37). Pp. 222-239. (in English).
  17. Prinuditel'noye litsenzirovaniye: zarubezhnyy opyt [Compulsory licensing: foreign experience]. Bulletin on the development of competition. Analytical Center under the Government of the Russian Federation. December 2017.
  18. Rimmer, M. (2005) The Jean Chrétien Pledge to Africa Act: patent law and humanitarian aid, Expert Opinion on Therapeutic Patents, 15:7. Pp. 889-909. (in English).
  19. Reik, R. (1946). Compulsory Licensing of Patients. The American Economic Review, 36(5). Pp. 813-832 (in English).
  20. Salickaya, E.A. (2016) Prinuditel'noye litsenzirovaniye lekarstvennykh sredstv kak mekhanizm obespecheniya balansa publichnykh i chastnykh interesov [Compulsory licensing as a mechanism of ensuring balance between public and private interests]. Bulletin of Russian Academy of Science 2016, 86, № 5. Pp. 442-44. (in Russian).
  21. Vorogevich, A. (2017) Prinuditel'noye litsenzirovaniye farmpreparatov: chem opasny dlya otrasli i potrebiteley initsiativy FAS Rossii [Compulsory licensing of pharmaceuticals: what is the risk for the industry and consumers?] Economy and life, №1 (9667), Pp. 14-15. (in Russian).
  22. Van Overwalle, Geertrui (2006) The Implementation of the Biotechnology Directive in Belgium and its Aftereffects: The Introduction of a New Research Exemption and a Compulsory License for Public Health. International Review of Intellectual Property and Competition Law (IIC), Vol. 37. Pp. 889-920. (in English).

Copyright (c) 2019 Abashidze A.H., Malichenko V.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies